Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 22:37:100822.
doi: 10.1016/j.lanepe.2023.100822. eCollection 2024 Feb.

Gene replacement therapy in spinal muscular atrophy: filling the data gaps

Tim Hagenacker  1 , Ulrike Schara-Schmidt  2
Affiliations

Gene replacement therapy in spinal muscular atrophy: filling the data gaps

Tim Hagenacker et al. Lancet Reg Health Eur. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Tim Hagenacker declares institutional research support from Novartis, not related to the study. Ulrike Schara-Schmidt declares speaker fees, travel support and advisory board compensation from Novartis.

Similar articles

See all similar articles

Cited by

References

    1. Hagenacker T., Schara-Schmidt U., Kleinschnitz C. [Gene-based treatment in spinal muscular atrophy] Nervenarzt. 2022;93(6):549–556. - PubMed
    1. Day J.W., Finkel R.S., Chiriboga C.A., et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–293. - PubMed
    1. Mercuri E., Muntoni F., Baranello G., et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832–841. - PubMed
    1. Strauss K.A., Farrar M.A., Muntoni F., et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022;28(7):1381–1389. - PMC - PubMed
    1. Strauss K.A., Farrar M.A., Muntoni F., et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med. 2022;28(7):1390–1397. - PMC - PubMed

LinkOut - more resources